Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an investigational cell therapy product developed by the Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts in Paris, France, for the treatment of total limbal stem cell deficiency (LSCD). The therapy consists of autologous or allogeneic limbal epithelial stem cells cultured on a human amniotic membrane scaffold without the use of feeder cells. It is designed to be transplanted onto the ocular surface to restore the physiological function of the limbal epithelium, which is critical for maintaining corneal health and transparency. The product was evaluated in a Phase 2 clinical trial (TC181) to assess its ability to improve visual function and anatomical conditions of the ocular surface in patients with severe unilateral or bilateral limbal deficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epithelial stem cells cultured (CHNO Quinze-Vingts).